Last reviewed · How we verify
NCT04884087
EMA of Substance Use in Homeless Youth
NA trial testing Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day in Substance Use in 40 participants. Completed in 30 June 2021.
30 June 2021
Quick facts
| Lead sponsor | Nationwide Children's Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 24 February 2021 |
| Primary completion | 30 June 2021 |
| Estimated completion | 30 June 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day
- Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day
- Incentive Structure - fixed
- Incentive Structure - prize based
Conditions studied
- Substance Use — all drugs for Substance Use →
Sponsor
Nationwide Children's Hospital
Who can join
Adults 18 to 24, any sex, with Substance Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed study will provide critical information on Ecological Momentary Assessment (EMA) design characteristics that promote retention in a vulnerable and under-represented population in research-youth experiencing homelessness. The study will use an EMA app to collect substance use, mood, craving, social surroundings, and trauma measures over a 14-day period in youth age 18-24 (n=40) recruited from Star House, a homeless youth drop-in center. Youth will be randomized in 2x2 factorial design (fixed incentive model vs. prize-based model; random assessment 3x vs. 6x per day).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04884087
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Substance Use
Currently open trials in the same condition.
- NCT07075081 — Gii'Igoshimong: Sitting With Your First Family · Phase 2 · recruiting
- NCT05743699 — Adaptation and Evaluation of Bright Horizons · NA · recruiting
- NCT07509853 — Integrating Sexual Pleasure Into Harm Reduction Services for Men Who Have Sex With Men and Transgender Persons Who Engag · NA · recruiting
- NCT06899308 — Health Surveillance at Constructor University Bremen (CUB) and Among HAW-Hamburg Employees · recruiting
- NCT07512869 — Host Led Harm Reduction Approach Among Men Who Have Sex With Men Who Engaged in Chemsex in Bangkok, Thailand: A Pre-Impl · recruiting
Other Nationwide Children's Hospital trials
Trials by the same sponsor.
- NCT07035912 — Novel PIONEER© Protocol: RCT · NA · not yet recruiting
- NCT07435792 — TetraGraph to Evaluate Onset and Recovery Times of Rocuronium · NA · not yet recruiting
- NCT07026942 — Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML · Phase 1, PHASE2 · not yet recruiting
- NCT06795126 — Little NIRVANA for Pediatric Pain and Anxiety · NA · enrolling by invitation
- NCT06854991 — Healthy Children and Virtual Reality Mediation of Simulated Pain · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04884087 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nationwide Children's Hospital
- Last refreshed: 17 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04884087.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing